

May 28, 2025

To,  
Department of Corporate Service  
BSE Limited,  
Registered Office : Floor 25, P. J. Towers,  
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.  
T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

**Subject : Approval of Standalone Audited Financial Results for the quarter and year ended March 31, 2025 along with Declaration and Auditor's Report.**

**Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380**

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Audited Financial Results for the quarter and year ended March 31, 2025.
- 2). Statement of Assets and Liabilities as on March 31, 2025.
- 3). Statutory Auditor's Report for the year ended March 31, 2025.
- 4). Declaration with respect to audit report with unmodified opinion for the financial year ended on March 31, 2025.

The said meeting commenced at 05:00 p.m. and concluded at 05:35 p.m.

Kindly take the same on your record.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**



**MAHIMA** Digitally signed  
by MAHIMA  
**BATHWA** BATHWAL  
Date: 2025.05.28  
17:49:32 +05'30'

**Mahima BATHWAL**  
Membership No. ACS A35069  
Company Secretary & Compliance Officer

Enclosures : as mentioned above.

■ **Registered Office**  
F-29, MIDC, Murbad, Thane 421401.  
MAHARASHTRA.  
☎ 912524222905 Fax 912524222905

■ **Manufacturing Facility**  
B-17,F-29, 22, 23, 24 MIDC, Murbad,  
Thane 421401. MAHARASHTRA.  
☎ 2524223200 Fax 912524 222872

■ **Sales Office - Mumbai**  
1<sup>st</sup> Floor, Palai Complex CHS Ltd.,  
Bhandarkar Road, Matunga (East),  
Mumbai 400019. MAHARASHTRA.  
☎ 912224102876 Fax 912224161261

■ **Sales Office - Kolkata**  
Flat No. N-1, Ground Floor, 385,  
Purbachal, Kalitala Road, P.S. Kasba,  
Kolkata 700078. WEST BENGAL.  
☎ 91 3324844875 Fax 91 3324844875



Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2025

(Rs. in Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended	Year ended
		31/03/2025	31/12/2024	31/03/2024	31/12/2024	31/12/2023	31/03/2025	31/03/2024
		(Audited)	(Un-audited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
I	Revenue from Operations	1330.77	1219.88	1204.95	4020.85	3913.94	5,351.62	5118.89
II	Other Income	4.99	0.51	3.38	7.02	9.23	12.01	12.61
III	<b>Total Revenue (I + II)</b>	<b>1335.76</b>	<b>1220.39</b>	<b>1208.32</b>	<b>4027.87</b>	<b>3923.17</b>	<b>5363.63</b>	<b>5131.50</b>
IV	Expenses :							
	(a) Cost of Material Consumed	294.50	416.09	588.43	1361.89	1423.17	1656.38	2011.60
	(b) Purchase of Stock-in-Trade	-	-	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	59.51	(91.70)	(241.96)	6.90	(63.88)	66.42	(305.84)
	(d) Employee Benefits Expenses	304.70	318.99	317.57	881.16	815.76	1185.86	1133.33
	(e) Finance Cost	219.22	49.76	94.96	155.33	151.93	374.55	246.89
	(f) Depreciation and Amortisation Expenses	126.25	110.75	43.79	299.21	95.00	425.46	138.79
	(g) Other Expenses	465.34	501.27	390.52	1351.40	1388.90	1816.73	1779.43
	<b>Total Expenses (IV)</b>	<b>1469.52</b>	<b>1305.16</b>	<b>1193.31</b>	<b>4055.89</b>	<b>3810.88</b>	<b>5525.40</b>	<b>5004.20</b>
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	(133.76)	(84.77)	15.01	(28.02)	112.29	(161.78)	127.30
VI	Exceptional Items	-	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	(133.76)	(84.77)	15.01	(28.02)	112.29	(161.78)	127.30
VIII	Tax Expense :							
	(1) Current Tax	-	-	(4.01)	-	28.26	-	24.25
	(2) Deferred tax	(15.41)	-	-	-	-	(15.41)	(10.39)
	<b>Total Tax Expenses</b>	<b>(15.41)</b>	<b>-</b>	<b>(4.01)</b>	<b>-</b>	<b>28.26</b>	<b>(15.41)</b>	<b>13.86</b>
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	(118.35)	(84.77)	19.02	(28.02)	84.03	(146.37)	113.44
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X - XI)	-	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX + XII)	(118.35)	(84.77)	19.02	(28.02)	84.03	(146.37)	113.44
XIV	Other Comprehensive Income							
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	(118.35)	(84.77)	19.02	(28.02)	84.03	(146.37)	113.44
XVI	Earnings Per Equity Share (for Continuing operation) :							
	(a) Basic	(3.24)	(2.30)	0.52	(0.76)	2.30	(4.01)	3.11
	(b) Diluted	(3.24)	(2.30)	0.52	(0.76)	2.30	(4.01)	3.11
XVII	Earnings Per equity share (for Discontinued operation) :							
	(a) Basic	-	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (for Discontinued & Continuing operation) :							
	Basic (Rs.)	(3.24)	(2.30)	0.52	(0.76)	2.30	(4.01)	3.11
	Diluted (Rs.)	(3.24)	(2.30)	0.52	(0.76)	2.30	(4.01)	3.11



For  
**CENTENIAL**  
 SURGICAL SUTURE LTD.  
 Managing Director  
 DIN:00094800




**Notes:**

- 1). The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on May 28, 2025
- 2). The Company has one reportable business segment "Medical Devices".
- 3). In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out audit of the Standalone Audited Financial Results for the Quarter and Year ended March 31, 2025.
- 4). The Company's Operation consists only one segment; hence Segment reporting under AS17 is not applicable.
- 5). Previous year figures have been regrouped or reclassified wherever necessary .
- 6). There is no proceeds of public issue, rights issue , preferential issue, qualified institutions placement, etc., therefore statement on the same is not forming part of this results.
- 7). There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- 8). As per the Master Circular dated November 11, 2024 company is not required to give disclosure as per B and C point as not applicable for the current quarter.
- 9). The Standalone Audited Financial Results for the Quarter and Year ended March 31, 2025 are available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on Company's website at [www.centenialindia.com](http://www.centenialindia.com).

for and on behalf of the Board of Directors of  
for **CENTENIAL SURGICAL SUTURE LTD.**

Place : Mumbai, Maharashtra

Date : May 28, 2025



Vijay MAJREKAR  
Managing Director ~ DIN : 00804808



## Statement of Assets and Liabilities

Rs. In Lakhs


	Particulars	As at March 31, 2025	As at March 31, 2024
I	ASSETS		
1)	Non-current assets		
	a) Property, Plant and Equipment	1810.68	1017.42
	b) Right to Use Assets	187.60	259.28
	c) Other Intangible assets	0.42	0.53
	d) Financial assets	-	-
	(i) Loans	-	-
	(ii) Other financial assets	46.81	46.99
	e) Deferred tax assets (net)	2.98	-
	f) Income-tax assets (net)	87.77	24.22
	g) Other non-current assets	25.82	34.92
	Total Non-current assets (1)	2162.08	1383.35
2)	Current assets		
	a) Inventories	4348.13	4251.54
	b) Financial assets		
	(i) Trade receivables	1839.64	1880.44
	(ii) Cash and cash equivalents	21.95	68.46
	(iii) Bank balances other than (ii) above	-	-
	(iv) Loans	-	-
	(v) Other current financial assets	-	-
	c) Other current assets	86.67	331.41
	Total Current assets (2)	6296.39	6531.86
	TOTAL ASSETS (I = 1 + 2)	8458.47	7915.21
II	EQUITY & LIABILITIES		
1)	Equity		
	a) Equity Share capital	542.43	542.43
	b) Other Equity	2533.06	2679.39
	Total Equity (1)	3075.49	3221.83
2)	Liabilities		
	Non-current liabilities		
	a) Financial Liabilities		
	(i) Other financial liabilities	2200.03	1395.97
	b) Long-term provisions	-	-
	c) Deferred tax liabilities (net)	-	12.43
	Total Non-current liabilities	2200.03	1408.40
	Current liabilities		
	a) Financial Liabilities		
	(i) Trade payables	717.34	971.30
	(ii) Borrowings	1225.78	1444.42
	(iii) Other current financial liabilities	617.59	445.23
	b) Other current liabilities	622.25	424.04
	c) Short-term provisions	-	-
	Total Current liabilities	3182.96	3284.99
	Total Liabilities (2)	5382.98	4693.38
	TOTAL EQUITY AND LIABILITIES (II = 1 + 2)	8458.47	7915.21



## Cash Flow Statement for the Quarter and Year ended March 31, 2025

Rs. In Lakhs

Particulars	As at March 31, 2025	As at March 31, 2024
<b>A. Cash flow from operating activities</b>		
Net Profit before tax	(161.78)	127.30
Adjustments for :		
Depreciation and amortisation expense	425.46	138.79
Interest income	(4.04)	(8.03)
Finance Cost	374.55	246.89
Exchange gain	(7.96)	(4.56)
Provision for Leave encashment	-	-
Provision for Gratuity	25.82	34.92
Sundry balances written back/written-off	-	-
<b>Operating profit before working capital changes</b>	<b>652.05</b>	<b>535.31</b>
Adjustments for :		
Decrease / (Increase) in inventories	(96.59)	(527.28)
Decrease / (Increase) in trade receivable	40.80	178.91
Decrease / (Increase) in long term loans and advances and other receivables	-	-
Decrease / (Increase) in financials and non-financial assets	(27.76)	(32.84)
Decrease / (Increase) in other assets and receivables	244.74	(210.97)
(Decrease) / Increase in trade and other payables	920.67	719.35
<b>Cash generated from operations</b>	<b>1733.91</b>	<b>662.48</b>
Income tax refund / (paid)	(26.50)	(41.00)
<b>Net cash (used in) / generated from operating activities</b>	<b>1707.40</b>	<b>621.47</b>
<b>B. Cash flow from investing activities</b>		
Acquisition of fixed assets and capital work in progress	(1146.91)	(769.60)
Proceeds from sale of investments	-	-
Interest income on fixed deposits and other advances	(13.82)	(22.33)
<b>Net cash (used in) / generated from investing activities</b>	<b>(1160.73)</b>	<b>(791.94)</b>
<b>C. Cash flow from financing activities</b>		
Finance Cost	(374.55)	(246.89)
Proceeds from Short term borrowings	(218.64)	452.83
<b>Net cash (used in) / generated from financing activities</b>	<b>(593.19)</b>	<b>205.93</b>
<b>Net (decrease) / increase in cash and cash equivalents (A+B+C)</b>	<b>(46.52)</b>	<b>35.46</b>
Cash and cash equivalents as at the beginning of year	68.46	33.00
<b>Cash and cash equivalents at the end of year</b>	<b>21.95</b>	<b>68.46</b>
<b>Components of cash and cash equivalents (Also, refer note 10)</b>		
Cash in hand	1.72	1.46
Balance with scheduled banks in current accounts	20.23	67.00
<b>Total</b>	<b>21.95</b>	<b>68.46</b>





**Independent Auditor's Report on the quarterly and year to date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Members of  
Centenial Surgical Suture Limited  
Report on the Audit of the Standalone Financial Statements**

**Opinion**

We have audited the accompanying statement of quarterly and year to date standalone financial results of **CENTENIAL SURGICAL SUTURE LIMITED** ("the Company") for the quarter and the year ended March 31, 2025 as well as the year-to-date results for the period from April 1, 2024 to March 31, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 as well as the year-to-date results for the period from April 1, 2024 to March 31, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



## **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matters**

The Statement includes the results for the quarter ended March 31, being the balancing figure between the audited figures in respect of the full financial year ended March 31, and the published unaudited year-to-date figures up to the third quarter of the financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our report on the Financial Statements is not modified in respect of this matter.

**For Mahesh Chandra and Associates**  
**Chartered Accountants**  
Firm's Registration No. 112334W

**ADITYAVI** Digitally signed by  
**KRAM** ADITYAVIKRAM  
**BOHRA** BOHRA  
Date: 2025.05.28  
17:51:47 +05'30'

**Adityavikram Bohra**  
**Partner**  
Membership No.: 193223

Mumbai, Maharashtra  
Dated : May 28, 2025

**UDIN: 25193223BMLCFT4772**



May 28, 2025

To,  
Department of Corporate Service  
BSE Limited,  
Registered Office : Floor 25, P. J. Towers,  
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.  
T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

**Subject : Declaration with respect to Auditor's Report with unmodified opinion for the Financial Year ended March 31, 2025.**

**Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380**

Dear Sir,

I Anuradha Kashikar, Chief Financial Officer of Centenial Surgical Suture Ltd., Corporate Identification Number: L99999MH1995PLC089759, having registered office at F-29, MIDC, Murbad, Thane 421401. MAHARASHTRA, hereby declare that the M/s. Mahesh Chandra & Associates, Chartered Accountants, Firm Registration No. 112334W the Statutory Auditors of the company represented by its Partner Adityavikram Bohra holding Membership No. 193223 have issued an audit report with unmodified opinion on Audited Financial Results for the Quarter and Year Ended March 31, 2025.

The declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide its circular no CIR/CFDICMDI56/2016 dated 27th May, 2016.

This is for your information and Records.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**



ANURADHA  
RAGHUNAN  
DAN  
KASHIKAR  
Digitally signed by  
ANURADHA  
RAGHUNANDAN  
KASHIKAR  
Date: 2025.05.28  
17:51:38 +05'30'

Anuradha Kashikar  
Chief Financial Officer

■ **Registered Office**  
F-29, MIDC, Murbad, Thane 421401.  
MAHARASHTRA.  
☎ 912524222905 Fax 912524222905

■ **Manufacturing Facility**  
B-17, F-29, 22, 23, 24 MIDC, Murbad,  
Thane 421401. MAHARASHTRA.  
☎ 2524223200 Fax 912524 222872

■ **Sales Office - Mumbai**  
1<sup>st</sup> Floor, Palai Complex CHS Ltd.,  
Bhandarkar Road, Matunga (East),  
Mumbai 400019. MAHARASHTRA.  
☎ 912224102876 Fax 912224161261

■ **Sales Office - Kolkata**  
Flat No. N-1, Ground Floor, 385,  
Purbachal, Kalitala Road, P.S. Kasba,  
Kolkata 700078. WEST BENGAL.  
☎ 91 3324844875 Fax 91 3324844875

®

CENTENIAL

www.centenialindia.com | ISO 9001 : 2015 / ISO 13485 : 2016 certified company